FDA approves GSK’s Jideytro for previously treated ROS1-positive NSCLC - GSK News | RalliesFDA approves GSK’s Jideytro for previously treated ROS1-positive NSCLC
G
GSK• FDA approves Jideytro for previously treated ROS1-positive NSCLC
- FDA cleared GSK’s Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 inhibitor.
- Green light came ahead of the Sept. 18, 2026, target action date.
- Approval was backed by ARROS-1 data showing a 44% objective response rate in 117 patients.
•
